Disease-Vaccine-Landing-Page/Respiratory-Syncytial-Virus-(RSV)/Can-RSV-vaccine-cause-injury-death

In pre-licensing clinical trials, the most frequently reported side effect was injection site pain. Within seven days of receipt of MRESVIA, the most commonly reported systemic adverse events included fatigue,...

According to data released December 27, 2024 by the CDC, 7,128 adverse reactions, including 60 deaths and 477 hospitalizations, have been reported to the Vaccine Adverse Events Reporting System (VAERS). ...

On July 17, 2023, the FDA approved the drug nirsevimab under the trade name Beyfortus, a monoclonal antibody, for the prevention of RSV in infants and children up to 24...

In pre-licensing clinical trials, the most frequently reported side effect was pain at the injection site. Within four days of receipt of the vaccine, the most commonly reported systemic adverse...

During clinical trials for ABRYSVO, in persons 60 years of age and older, the most commonly reported adverse events included swelling, pain, and redness at the injection site, fatigue, headache,...